Navigation Links
New Therapy Kills Human Leukemia Cells in Mice
Date:5/16/2008

Technique expands natural killer cells in cord blood more than 30-fold

FRIDAY, May 16 (HealthDay News) A treatment that uses natural killer (NK) immune system cells from umbilical cord blood effectively destroys human leukemia cells in mice, researchers say.

The NK cells reduced by 60 percent to 85 percent human acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML) cells in test mice with aggressive human leukemias, according to the study.

The findings are to be presented at the May 16 American Society of Pediatric Hematology/Oncology annual conference, in Cincinnati.

Previous efforts like this one, which require the number of NK cells from a single cord blood to be expanded, resulted in ineffective NK cells. The new technique manages to increase NK cells in cord blood more than 30-fold while allowing the cells to retain their ability to target and kill acute leukemia cells.

"Cord blood is a promising source of natural killer cells, because the NK cells have enhanced sensitivity to stimulation, decreased potential to cause graft-versus-host disease and are available from cord banks throughout the country and world," investigator Dr. Patrick Zweidler-McKay, assistant professor of pediatrics from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center, said in a prepared statement.

Graft-versus-host disease is a common side effect of patients receiving stem cell transplants. It is fatal if not controlled.

The new process allows the NK cells to be transplanted to leukemia patients without the need for prior chemotherapy. Zweidler-McKay said that adults who have already had a transplant, or any age leukemia patient who is not eligible for other stem cell transplants due to blood counts or illness, may be available to use his new transplant method.

"These NK cells demonstrate significant cytotoxic activity against human AML an
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
2. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
3. Adding epratuzumab to standard therapy
4. Chemotherapy might help cancer vaccines work
5. The American College of Cardiology, American Heart Association and the Heart Rhythm Society Release Updated Cardiac Device-Based Therapy Guidelines
6. Drug therapy to bolster immune system cells found effective toward childhood cancer
7. Targeted therapy plus chemotherapy may pack 1-2 punch against melanoma
8. Blacks not receiving chemotherapy for rectal cancer, despite seeing cancer specialists
9. Drug therapy for PKU reverses heart damage
10. Therapy Yields Promise for Fatal Neurological Condition
11. Mayo Clinic study shows acupuncture and myofascial trigger therapy treat same pain areas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 Hastings and Hastings, a law ... a record number of legal representation client review requests for ... been a steady rise in the number of slip and ... home throughout the Valley. With that said, a large number ... by an experienced law firm. Hastings and Hastings is a ...
(Date:1/22/2015)... 22, 2015 Liberty University has received accreditation ... program from the Council for Accreditation of Counseling & ... Liberty’s Center for Counseling & Family Studies , is ... the university’s new School of Behavioral Sciences. Prior to the ...
(Date:1/22/2015)... 2015 Woodloch Pines, an all-inclusive family ... by TripAdvisor as the number one best large hotel for ... the world for their annual Travelers’ Choice Awards. , ... The website is home to millions of unbiased and honest ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who consistently ... thrilled to have it lead the wedding dress industry into ... prom dresses for the global market. , “The CEO of ... he focuses on continuing the goal of operational excellence and ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2
... efficient to use the drug cetuximab only in colorectal cancer ... a study published online August 7 in the Journal ... tumors harbored wild-type KRAS were found to have a higher ... by the National Cancer Institute of Canada Clinical Trials Group. ...
... Provides Protection for People with Lupus and other Chronic Diseases ... Lupus Foundation of America (LFA) President and Chief Executive Officer, Sandra ... Access to Prescription Medications Act of 2009" introduced on Thursday, ... , , "We support and ...
... , , MORRISTOWN, N.J., Aug. 7 ... specialty pharmaceutical company, announced today that one lot of 100 mcg/hr ... voluntarily recalled from wholesalers and pharmacies. The recalled patches are ... were manufactured by Watson Laboratories, Inc. and distributed by Watson Pharma, ...
... , NEW YORK, Aug. 7 Duane ... Reade Inc. and Duane Reade (collectively, the "Issuers"), had closed ... Secured Notes due August 1, 2015 (the "Notes"). The ... The Notes were priced at 97.417%, representing a yield to ...
... time for decisions, , FRIDAY, Aug. 7 (HealthDay News) -- ... serious complications for themselves and their moms. , Among single-baby ... "breech presentations," with the baby,s bottom, rather than head, positioned ... numbers are small, experts say the risks can be big. ...
... keep new beta cells under control , FRIDAY, Aug. 7 ... that plays a key role in the conversion of pancreas ... to a new treatment for type 1 diabetes. , In ... called Pax4 is turned on in pancreatic cells, the cells ...
Cached Medicine News:Health News:Cost-effectiveness of cetuximab in metastatic colorectal cancer 2Health News:The Lupus Foundation of America Applauds New Legislation that Caps Out-of-Pocket Drug Costs 2Health News:Watson Announces Limited Recall Of Fentanyl Transdermal System 2Health News:Watson Announces Limited Recall Of Fentanyl Transdermal System 3Health News:Duane Reade Holdings, Inc. Announces Closing of Offering of $300 Million of 11.75% Senior Secured Notes Due 2015 2Health News:Duane Reade Holdings, Inc. Announces Closing of Offering of $300 Million of 11.75% Senior Secured Notes Due 2015 3Health News:If Baby Is Breech, Technology Might Help 2Health News:If Baby Is Breech, Technology Might Help 3
(Date:1/23/2015)... , Jan. 23, 2015  MedScope ( www.medscope.org ), ... nominated for a 2015 Connected World magazine ... Response System (mPERS), that can be used anywhere, anytime. ... partner.  In nominating MedScope, Landon ...
(Date:1/23/2015)... all-time hits leader, is the new spokesperson for the topical ... announced. "Pete,s a Hall of Famer in our ... with Myoflex," said Ducere Pharma Chief Executive Officer Chris ... across all generations. The passion and intensity that Pete brought ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Rochester Medical's line ... the intermittent catheters you ... All four product configurations ... and antibacterial hydro - ...
... easy on delicate urethral tissues. ... hydrophilic coating provide nearly friction-free ... It's easy to maintain sterility. ... with its own sterile water, ...
... Rochester Medical's line ... the intermittent catheters you ... All four product configurations ... and antibacterial hydro - ...
... Rochester Medical's line ... the intermittent catheters you ... All four product configurations ... and antibacterial hydro - ...
Medicine Products: